NCT04952168

Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

A Single Arm, Prospective, Open Clinical Study of Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC With EGFR Mutation

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 26 (estimated)
• Sponsor: Yuan Chen · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Prospective, open, single arm study to evaluate the efficacy and safety of the almonertinib combined with concurrent chemoradiotherapy in unresectable stage III NSCLC with EGFR mutation

Conditions

• NSCLC, Stage III

Interventions

Type	Name	Description
DRUG	Almonertinib	All patients were treated with Almonertinib 110 mg once a day for 3 months. Patients evaluated as CR, PR and SD were given concurrent chemoradiotherapy. The dose of radiotherapy was 60-66Gy/30-33F, After the end of concurrent chemoradiotherapy, the patients were treated with 110 mg of ametinib once a day until the disease progressed or the side effects were intolerable.

Timeline

• Start date: 2021-06-02
• Primary completion: 2022-06-02
• Completion: 2023-06-02
• First posted: 2021-07-07
• Last updated: 2021-07-07

Locations

1 site across 1 country: China